Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: DENV is the most globally prevalent mosquito-transmitted virus. Induction of a broadly and potently immune response is desirable for dengue vaccine development.
Methods: Several formulations of secreted tetravalent EDIII protein containing different amounts of antigen from eukaryotic cells were used to evaluate the immune responses in mice.
Results: We demonstrated that the tetravalent protein induced humoral immunity against all four serotypes of DENV, even at the lowest dose assayed. Besides, cellular immunities against DENV-1 and DENV-2 were elicited by medium dose group. Importantly, the immune responses induced by the tetravalent protein were functional in clearing DENV-2 in circulation of mice.
Conclusions: We believe that the tetravalent secreted EDIII protein is a potential vaccine candidate against DENV and suggest further detailed studies of this formulation in nonhuman primates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.meegid.2020.104427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of tobacco chloroplast vector with novel insertion sites for dengue virus (DENV) antigens.
Protoplasma
July 2025
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Dengue virus (DENV) is a substantial global health threat with no specific antiviral treatment available. The development of effective vaccines is crucial to combat DENV infections. Plant-based expression systems, such as tobacco chloroplasts, have emerged as promising platforms for the production of DENV antigens.
View Article and Find Full Text PDFExtracellular Expression and Diagnostic Potential of Dengue Virus Type 3 E Protein Domain III Through Codon Optimization in Komagataella phaffii.
Mol Biotechnol
July 2025
Laboratory of Microorganism Physiology, Department of Biomedical Sciences and Health, Universidade do Estado de Minas Gerais (UEMG), Rua Sabará, 164, Centro, Passos, MG, CEP: 37900-004, Brazil.
Dengue is a mosquito-borne viral disease caused by the dengue virus (DENV), which affects millions worldwide. The envelope (E) protein, particularly domain III (EDIII), plays a critical role in viral entry and is a major target for diagnostic and vaccine development. In this study, we aimed to express and purify EDIII from DENV-3 using Komagataella phaffii as an expression system.
View Article and Find Full Text PDFA Scoping Review of Preclinical Research on Monoclonal Antibody Development for Prophylaxis and Treatment of West Nile Virus Infections.
Viruses
June 2025
Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA.
West Nile virus (WNV) causes thousands of arboviral infections in the United States each year. Patients with immune-compromising conditions and elderly people are at higher risk of severe WNV neuroinvasive disease (WNND). Despite its broad endemicity nationwide, no U.
View Article and Find Full Text PDFA High-Affinity and Potently Neutralized Nanobody against Zika Virus.
ACS Infect Dis
July 2025
Health Inspection and Quarantine Laboratory, Guangzhou Customs Technology Center, Guangzhou 510623, China.
ZIKA virus (ZIKV), an emerging pathogen for which no licensed drugs or vaccines exist, has attracted global attention. ZIKV envelope protein domainIII (EDIII) can induce neutralizing antibodies with minor cross-reactive epitopes among flaviviruses. Currently, no nanobodies against the ZIKV EDIII protein are available.
View Article and Find Full Text PDFVirus-Like Particle-Based Multiserotype Quartet Vaccine of Dengue Envelope Protein Domain III Elicited Potent Anti-Dengue Responses.
Biomacromolecules
July 2025
Laboratory of Biotechnology, Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan.
In this study, we presented two strategies for designing an envelope domain III (EDIII)-based tetravalent dengue virus (DENV) vaccine. The first approach was conjugation of the EDIIIs from all four DENV serotypes to a norovirus-like particle (NoV-LP) scaffold, yielding the NoV::tetEDIII vaccine. The second approach linked the EDIIIs of all four serotypes into a single polypeptide chain, which was also conjugated to the NoV-LP scaffold by using the SpyTag/SpyCatcher system, creating the NoV::quartetEDIII vaccine.
View Article and Find Full Text PDF